INT-767, a dual FXR and TGR5 agonist, potently increases intracellular Ca2+ level, cAMP concentration, and GLP-1 secretion and regulates gene expression involved in the BA synthesis, thus it exerts potent therapeutic benefits against NASH (Pathak et al., 2017; Wang et al., 2018). This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.